Breast Cancer Now media statements
We welcome approval of palbociclib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS w...
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo f...
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the...
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England's proposed new standards
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new data from major trial OlympiA shows adjuvant olaparib improved survival in patients
On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society for Medical ...
We respond to research about artificial sweeteners and breast cancer risk
Commenting on research published in PLOS Medicine about artificial sweeteners and breast cancer risk, Dr Kotryna Temcinaite, Senior Research...
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: